Studies in preclinical models have demonstrated robust anti-inflammatory and neuroprotective effects of RNS60. Protocol development is underway for a Phase II clinical study that will evaluate the effect of RNS60 on progression of MS in patients.
So they are still designing the study. Has anyone called them regarding when they think it will happen?
On the bottom of this page, they appear to be looking for partners (I am guessing funding)
Revalesio is seeking partners for the continued development of RNS60.
hmmm... just noticed there was a poster at the 2011 ANN